During the BIO International Convention in San Diego, SK Biopharmaceuticals CEO Lee Dong-hoon expressed confidence in establishing the company as a leading provider of anti-epilepsy treatments. He highlighted the success of Xcopri in the US market, contributing to the company's strong performance in the first quarter of the year. Lee emphasized the company's commitment to long-term success through its own research and development pipeline, with a focus on exploring new pharmaceutical modalities. SK Biopharmaceuticals also announced their participation in 200 meetings during the convention, with a focus on pipeline partnering, acquisitions, and development. Furthermore, Lee discussed the company's achievements, including the sales growth of Xcopri and the potential for $1 billion in US sales by 2029. He also emphasized the importance of recruiting top talent globally and hinted at the acquisition of a new product by the end of the year to support further research and development efforts. This marked the first time that SK Group's bio affiliates, SK Biopharmaceuticals and SK Bioscience, participated in the BIO USA event, showcasing their technology and portfolios to enhance global business partnerships.